The global High Grade Glioma Market is expected to have a steady revenue CAGR over the forecast period due to several factors, including the increasing prevalence of brain cancer and greater social awareness of various types of gliomas. High-grade gliomas are glial cell tumors that can develop in the brain and spinal cord, and they are challenging to cure due to their rapid development and spread through brain tissue.
Children of all ages, from newborns to adults, can develop these tumors, and both males and females are affected. High radiation therapy doses can occasionally cause high-grade gliomas, but the majority of these tumors in children have an unknown origin.
Get a free sample PDF of the report, visit @
https://www.reportsanddata.com/download-free-sample/5491
Some of the factors that drive the growth of the global high-grade glioma market include the rising number of cases registered in various countries worldwide. For example, in the United States, the prevalence of HGG (grade III and IV) is about 3.56 per 100,000 people, and in Taiwan, it is 1.04 per 100,000 people.
Key players in the High Grade Glioma Market –
- Sun Pharmaceutical Industries Ltd.
- Amgen, Inc.
- Teva Pharmaceutical Industries Ltd
- The Bristol-Myers Squibb Company
- Pfizer, Inc.
- Merck KGaA
- F. Hoffmann-La Roche Ltd.
High-grade gliomas are more common among females and children aged between 1 and 9 years old, and people with lighter skin tone are more susceptible to this condition than those with darker skin tone. However, the market's revenue growth is likely to be hampered by issues related to product approval and commercialization, side effects of treatment drugs, and inadequate knowledge about brain cancer and its treatment.
The requirement for effective therapy has grown as the incidence rate of brain tumors has increased, leading multinational corporations to invest significant amounts of their earnings in RD to create innovative pharmaceuticals. Novel drugs to treat brain tumors are in demand, and there are several items related to advanced medication delivery systems waiting for FDA approval. North America is expected to have the largest market share during the forecast period, owing to higher rates of diagnosis and treatment for various rare disorders, among other factors. The Asia Pacific region is expected to register a steady revenue CAGR over the forecast period due to rising demand for blood thinner drugs and anticoagulants, as well as government initiatives to invest more in healthcare infrastructure.
Notable Innovations in the High Grade Glioma Market –
There have been several notable innovations in the high-grade glioma market in recent years. Some of these include:
- Immunotherapy: Immunotherapy is a promising new approach to treating high-grade gliomas. This approach involves stimulating the immune system to attack cancer cells. One example of an immunotherapy drug being studied for high-grade glioma treatment is nivolumab.
- Gene therapy: Gene therapy involves altering the genes in cancer cells to prevent them from growing or spreading. This approach is still in the early stages of development, but there have been some promising results in animal studies.
- Targeted therapy: Targeted therapy involves using drugs that specifically target the genetic mutations that are driving the growth of high-grade gliomas. For example, drugs that target the IDH1 and IDH2 mutations have shown promise in clinical trials.
- Drug delivery systems: New drug delivery systems are being developed to help drugs reach the brain more effectively. These include nanoparticles that can cross the blood-brain barrier and convection-enhanced delivery (CED) systems that allow drugs to be infused directly into the brain.
- Precision medicine: Precision medicine involves tailoring treatment to the specific genetic mutations that are driving a patient's high-grade glioma. This approach is still in the early stages of development, but it holds promise for improving treatment outcomes in the future.
In 2020, AstraZeneca-SciLifeLab research collaborated to create a drug biobank to treat glioblastoma, a type of glioma. A total of 1,544 drugs were compared with changes in glioblastoma cells, which may be used to repurpose drugs and discover new treatments. Additionally, Fabio Iwamoto, MD in collaboration with Bristol-Myers Squibb, is developing a drug to test the safety and efficacy of Nivolumab, currently in Phase 2, to treat recurrent or progressive IDH Mutant Gliomas. Ivy Brain Tumor Center has partnered with GSK to evaluate and carry out Phase 0 for Niraparib in treating patients with Brain Cancer, a drug to be used in patients with newly diagnosed glioma and recurrent grade II-IV gliomas.
The market is segmented by treatment outlook, route of administration outlook, distribution channel outlook, end-user outlook, and region outlook. The treatment outlook includes chemotherapy, targeted drug therapy, and other treatments. The route of administration outlook includes oral, parenteral, and other administration routes. The distribution channel outlook includes online and offline channels. The end-user outlook includes hospital pharmacy, retail pharmacy, and online pharmacy. The region outlook includes North America, Europe, Asia Pacific, and other regions.
Request customization of the report @
https://www.reportsanddata.com/request-customization-form/5491
Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure the report is well suited to meet your requirements.
Browse for more reports:
https://www.reportsanddata.com/report-detail/cord-blood-banking-services-market
https://www.reportsanddata.com/report-detail/immunohematology-market
https://www.reportsanddata.com/report-detail/retinal-surgery-devices-market
https://www.reportsanddata.com/report-detail/cell-culture-protein-surface-coating-market
https://www.reportsanddata.com/report-detail/dental-autoclaves-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
